

Standalone Unaudited Financial Results for the Quarter & Nine months ended on 31.12.13
PART-I

(Rs. in Lacs except per share data)

No.	Particulars	Quarter Ended			9 Month Ended		Year Ended
		Unaudited			Unaudited		Audited
		31.12.13	30.09.13	31.12.12	31.12.13	31.12.12	31.03.13
1	Income from Operations						
	(a) Net Sales/Income from Operations	1948.38	1974.87	1762.80	5626.8	5207.85	6927.00
	(b) Other Operating Income	0.00	0.78	0.00	2.15	0.00	7.25
	Total Income from Operations (Net)	1948.38	1975.65	1762.80	5628.95	5207.85	6934.25
2	Expenses						
	(a) Cost of Materials Consumed	716.39	623.36	642.37	1806.70	1832.83	2362.93
	(b) Purchases of Stock in Trade	0.00	0.00	0.12	0.00	0.90	11.22
	(c) Changes in Inventories of Finished Goods, Work-in-progress and Stock-in-Trade	-126.71	61.05	-63.96	14.39	-115.18	-88.62
	(d) Employee benefits Expense	429.71	410.06	422.22	1273.81	1248.73	1580.66
	(e) Depreciation and amortisation Expense	37.50	39.00	24.00	112.50	74.00	148.29
	(f) Other Expenses	614.60	543.40	551.02	1658.18	1517.98	2056.93
	Total Expenses	1671.49	1676.87	1575.77	4865.58	4559.26	6071.41
3	Profit from Operations before other income, finance cost and exceptional items (1-2)	276.89	298.78	187.03	763.37	648.59	862.84
4	Other Income	51.76	36.79	37.41	89.65	55.92	111.95
5	Profit from Ordinary activities before finance costs and exceptional items (3+4)	328.65	335.57	224.44	853.02	704.51	974.79
6	Finance Cost	58.24	20.83	8.44	129.27	58.11	93.80
7	Profit from ordinary activities after finance cost but before exceptional items (5-6)	270.41	314.74	216.00	723.75	646.40	880.99
8	Exceptional Income	0.00	0.90	0.00	0.90	0.00	1.39
9	Profit from Ordinary activities before tax (7+8)	270.41	315.64	216.00	724.65	646.40	882.38
10	Tax Expense	75.00	85.00	72.00	205.00	192.00	260.85
11	Net Profit from Ordinary activities after tax (9-10)	195.41	230.64	144.00	519.65	454.40	621.53
12	Extra ordinary items	0.00	0.00	0.00	0.00	0.00	0.00
13	Net Profit for the period (11+12)	195.41	230.64	144.00	519.65	454.40	621.53
14	Paid-up Equity Share Capital (face value of Rs.10/- each.)	464.93	464.93	464.93	464.93	464.93	464.93
15	Reserves and surplus	0.00	0.00	0.00	0.00	0.00	1800.17
16	Earnings per share (EPS)						
	EPS (before & after extra ordinary items- Basic & Diluted)	4.20	4.96	3.10	11.18	9.77	13.37

Contd...2/-



*** 2 ***

PART-II INFORMATION FOR THE QUARTER AND NINE MONTHS ENDED ON 31.12.2013


Sr. No.	Particulars	Quarter Ended			9 months ended		Year Ended
		31.12.13	30.09.13	31.12.12	31.12.13	31.12.12	31.03.13
		Unaudited					Audited
A.	Particulars of Shareholding						
1	Public shareholding						
	- Number of shares	2479955	2486458	2517227	2479955	2517227	2500928
	- Percentage of shareholding	53.34	53.48	54.14	53.34	54.14	53.79
2	Promoters and Promoter Group Shareholding						
	a) Pledged / Encumbered						
	- Number of shares	0	0	0	0	0	0
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0	0	0	0	0	0
	- Percentage of shares (as a % of the total share capital of the company)						
	b) Non - encumbered						
	- Number of shares	2169345	2162842	2132073	2169345	2132073	2148372
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	46.66	46.52	45.86	46.66	45.86	46.21
	Particulars	Quarter ended on 31.12.2013					
B	INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter				Nil		
	Received during the quarter				1		
	Disposed of during the quarter				1		
	Remaining unresolved at the end of the quarter				Nil		

Notes:

1. The above unaudited financial results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meetings held on 29.01.2014.
2. The Limited Review of the above results has been carried out by the Statutory Auditors.
3. The Company is dealing exclusively in Pharmaceuticals Business Segment, hence segmentwise presentation of financial results is not required.
4. Prior period figures have been rearranged / regrouped wherever necessary for comparative purposes.

 Place : Mumbai
 Date : 29/01/2014

 By order of the Board,
 For Jenburkt Pharmaceuticals Ltd.



 (Ashish U. Bhuta)
 Chairman and Managing Director.

LIMITED AUDIT REVIEW REPORT

Review Report to the Board of Directors,
JENBURKT PHARMACEUTICALS LTD.
Nirmala Apartments, 93, J.P.Road,
Andheri (W),
Mumbai - 400 058.

We have reviewed the accompanying statement of unaudited financial results of JENBURKT PHARMACEUTICALS LIMITED for the quarter ended on 31st December, 2013 except for the disclosures regarding "Public shareholding and Promoter and Promoter Group Shareholding" which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Revised Standard on Review Engagements 2400, "Engagements to Review Financial Statements", issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying financial statements do not give a true and fair view (or are not presented fairly, in all material respects) in accordance with Financial Reporting Standards.

For D.L.ARORA & Co.
CHARTERED ACCOUNTANTS
Firm Regn. No.:100545W.

DILIP ARORA
PROPRIETOR
M.No.36152.



Place : Mumbai.

Date : 28.01.2014